Common Contracts
2 similar 3(a)(9) Exchange Agreement contracts by Corvus Pharmaceuticals, Inc., Eledon Pharmaceuticals, Inc.
Re: 3(a)(9) Exchange Agreement3(a)(9) Exchange Agreement • January 7th, 2021 • Eledon Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (the “Agreement”) confirms the agreement of Novus Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 509,117 shares (the “Shares”) of Common Stock, par value $0.001 per share (the “Common Stock”), beneficially owned by the Stockholders in consideration for one or more Common Stock Warrants in the form attached hereto as Exhibit A (each a “Warrant”) to purchase an aggregate of 509,117 shares of Common Stock (the “Warrant Shares”) on the terms specified below.
Re: 3(a)(9) Exchange Agreement3(a)(9) Exchange Agreement • November 12th, 2019 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (the “Agreement”) confirms the agreement of Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to which the Stockholders have agreed to exchange an aggregate of 1,458,000 shares (the “Shares”) of Common Stock, par value $0.0001 per share (the “Common Stock”), beneficially owned by the Stockholders in consideration for one or more Common Stock Warrants in the form attached hereto as Exhibit A (each a “Warrant”) to purchase an aggregate of 1,458,000 shares of Common Stock (the “Warrant Shares”) on the terms specified below.
